Prof. Jonathan Barratt (University of Leicester, UK) described a subanalysis of NefIgArd, a phase 3 trial assessing nefecon 16 mg/day versus placebo in adults with IgA nephropathy [1]. Trial participants had an eGFR between 35–90 mL/min/1.73 m2 and a urinary protein-creatinine ratio (uPCR) ≥0.1 g/day despite optimised RAS inhibitor treatment [2]. This subanalysis focused on the effect of therapy on eGFR decline over the 9 months of therapy and through 15 months of follow-up, and included 182 participants in each treatment group [1].
Among subgroups defined by eGFR deciles ( ≤38/>38, ≤43/>43, ≤47/>47, ≤51/>51, ≤55/>55, ≤60/>60, ≤66/>66, ≤72/>72, and ≤82/>82 mL/min/1.73 m2), nefecon versus placebo consistently showed improvement in eGFR after 9 months of treatment, but also at 12 months and 24 months of the trial during the follow-up period. Similarly, nefecon versus placebo led to an improvement in uPCR across all eGFR deciles and at the same assessed timepoints.
“This subanalysis of the NefIgArd study demonstrates that the efficacy of 9 months of nefecon treatment in the preservation of kidney function and reduction in proteinuria was independent of baseline eGFR,” concluded Prof. Barrat. “This effect was seen both after 9 months of treatment and throughout the remaining 15-month off-treatment period. I think we are going to see a lot more of these analyses as we have more and more treatments available because, as clinicians, we are seeing patients, and we need to best understand how particular patient phenotypes allow us to use one drug over another.”
- Barratt J, et al. Nefecon provides kidney benefit irrespective of baseline eGFR in patients with IgAN: A subanalysis of the NefIgArd study. 62nd ERA Congress, 4–7 June 2025, Vienna, Austria.
- Lafayette J, et al. Lancet. 2023;402(10405):859-870.
Medical writing support was provided by Mihai Surducan, PhD.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Iptacopan improves mesenchymal and capillary glomerular C3 deposition in patients with C3 glomerulopathy Next Article
Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease »
« Iptacopan improves mesenchymal and capillary glomerular C3 deposition in patients with C3 glomerulopathy Next Article
Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease »
Table of Contents: ERA 2025
Featured articles
Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy
Survival benefit from kidney transplantation depends on the donor source
Online First
Lumasiran shows continued promise in infants and young children with primary hyperoxaluria type 1
Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease
Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy
Sibeprenlimab is an emerging treatment option for IgA nephropathy
Pegcetacoplan is treatment option for adolescents with C3G or IC-MPGN
Mineral receptor antagonists not beneficial for patients undergoing dialysis
Spironolactone not useful in dialysis with cardiovascular risk
Acute eGFR dip following empagliflozin initiation not associated with acute kidney injury
Survival benefit from kidney transplantation depends on the donor source
Canagliflozin has dose-dependent effect on cardiovascular outcomes in patients with type 2 diabetes
Large meta-analysis shows empagliflozin slows kidney progression and reduces risk among patients with multiple diseases
Factor XI inhibition not useful for end-stage kidney disease patients receiving haemodialysis
Finerenone plus empagliflozin as new potential combination in patients with type 2 diabetes and chronic kidney disease
Related Articles

October 30, 2023
Heart failure: the 2023 update
February 18, 2021
Dapagliflozin reduces renal risk independent of CV disease status
November 5, 2020
Antisense ANGPTL3 lowers triglycerides
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com